Skip to main content

Advertisement

Log in

Poorer clinical outcomes for older adult monolinguals when matched to bilinguals on brain health

  • Original Article
  • Published:
Brain Structure and Function Aims and scope Submit manuscript

Abstract

Previous studies have reported bilingualism to be a proxy of cognitive reserve (CR) based on evidence that bilinguals express dementia symptoms ~ 4 years later than monolinguals yet present with greater neuropathology at time of diagnosis when clinical levels are similar. The current study provides new evidence supporting bilingualism’s contribution to CR using a novel brain health matching paradigm. Forty cognitively normal bilinguals with diffusion-weighted magnetic resonance images recruited from the community were matched with monolinguals drawn from a pool of 165 individuals in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. White matter integrity was determined for all participants using fractional anisotropy, axial diffusivity, and radial diffusivity scores. Propensity scores were obtained using white matter measures, sex, age, and education as predictive covariates, and then used in one-to-one matching between language groups, creating a matched sample of 32 participants per group. Matched monolinguals had poorer clinical diagnoses than that predicted by chance from a theoretical null distribution, and poorer cognitive performances than matched bilinguals as measured by scores on the MMSE. The findings provide support for the interpretation that bilingualism acts as a proxy of CR such that monolinguals have poorer clinical and cognitive outcomes than bilinguals for similar levels of white matter integrity even before clinical symptoms appear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Code availability

Available upon request.

References

Download references

Acknowledgements

Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Funding

Preparation of this manuscript was supported by grants R01HD052523 and R21AG048431 from the US National Institutes of Health and grant A2559 from the Natural Sciences and Engineering Research Council of Canada to EB.

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Author information

Authors and Affiliations

Authors

Consortia

Contributions

Matthias Berkes, Noelia Calvo, and Ellen Bialystok contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Matthias Berkes, Noelia Calvo, and John A. E. Anderson. The first draft of the manuscript was written by Matthias Berkes and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ellen Bialystok.

Ethics declarations

Conflict of interest

None.

Ethics approval

The research study was approved by York University’s Ethics Review Board and conforms to the standards of the Canadian Tri-Council Research Ethics guidelines.

Consent to participate

Bilingual participants signed written consent before the study and verbal assent throughout out. Monolingual participants were selected from the ADNI database where consent procedures were handled by ADNI.

Consent for publication

All authors consent to publication.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berkes, M., Calvo, N., Anderson, J.A.E. et al. Poorer clinical outcomes for older adult monolinguals when matched to bilinguals on brain health. Brain Struct Funct 226, 415–424 (2021). https://doi.org/10.1007/s00429-020-02185-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00429-020-02185-5

Keywords

Navigation